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Purpose: To analyze the cost of glaucoma medical therapy and compare it with that 
of surgical management in Nigeria.
Methods: The cost of glaucoma drugs and that of surgical therapy in patients who 
attended the eye clinic of the University of Benin Teaching Hospital, Benin City, 
Nigeria, between December 2002 and November 2008 were calculated over a 3 year 
period of follow-up. Costs of medical and surgical therapy were compared based 
on November 2008 estimates.
Results: One hundred and eight patients met the inclusion criteria of the study, 
of which, 90 patients (83.33%) received medical therapy and 18 patients (16.67%) 
underwent surgery. The most expensive drugs were the prostaglandin analogues, 
travoprost (Travatan) and latanoprost (Xalatan). The least expensive topical drugs 
were beta-blockers and miotics. The mean annual cost of medical treatment was 
US$ 273.47±174.42 (range, $41.54 to $729.23) while the mean annual cost of surgical 
treatment was US$ 283.78±202.95 (range, $61.33 to $592.63). There was no significant 
difference between the mean costs of medical and surgical therapy over the 3-year 
period (P = 0.37). Older age (P = 0.02) and advanced glaucoma (P < 0.001) were 
associated with higher costs of therapy. 
Conclusion: The cost of medical therapy was comparable to that of surgical therapy 
for glaucoma in Nigeria over a 3-year period.
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INTRODuCTION
Glaucoma is the second leading cause of 
blindness worldwide and is estimated to have 
affected 60.5 million people in 2010, increasing 
to 79.6 million by 2020.1 In glaucoma, the optic 
nerve is progressively damaged, causing defects 
in the visual field, usually asymptomatic until 
central vision is affected.2,3 Unfortunately, 
by the time characteristic visual field defects 
are demonstrable, one third or more of the 
optic nerve fibers are already damaged; by 
the time patients complain of significant field 
loss, the remaining axons are probably 10% or 
fewer.4 The purpose of glaucoma treatment is 
to preserve visual function while minimizing 
adverse effects of therapy, thereby enhancing 
patient health and quality of life.2,5,6 Although 
trabeculectomy is regarded as the standard 
form of treatment for patients with primary 
open angle glaucoma in developing countries 
including Nigeria,7 many glaucoma patients Cost of Glaucoma Treatment; Omoti et al
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are treated medically. This is especially true 
in teaching hospitals and other tertiary centers 
which are concentrated in urban areas, partly 
because of patients’ unwillingness to undergo 
surgery (since there will be no improvement 
in vision) and partly due to fear of surgery.8
Primary open angle glaucoma (POAG) 
requires lifelong monitoring; this places an 
increasing financial strain on the health service 
system as the elderly population increases. 
The volume and cost of glaucoma drugs have 
been shown to have increased dramatically 
in both Northern Ireland and the Republic of 
Ireland from 1996 to 2003, probably as a result 
of a combination of changing demographics 
and  a  changing  approach  towards  the 
management of patients with glaucoma and 
ocular hypertension.9 It has been demonstrated 
in Europe, that resource utilization and direct 
medical costs of glaucoma management increase 
with worsening disease severity.10 This has also 
been shown in the United States.11 However, 
there is a paucity of information on glaucoma 
therapy costs in Sub-Saharan Africa where 
patients frequently present with advanced 
stages of the disease.12 The purpose of this 
study is to analyze the cost of glaucoma drugs 
and compare it with that of surgical therapy 
in Benin City, Nigeria.
METHODS
Data was obtained from the medical records of 
all patients diagnosed with POAG and normal 
tension glaucoma, who attended the eye clinic 
of the University of Benin Teaching Hospital, 
Benin City, Nigeria, between December 2002 
and November 2008. The patients were included 
in the study if they had at least 3 years of 
continuous follow up. Only patients who were 
compliant with therapy were included in the 
study. Patients were included in the surgery 
group if they had primary trabeculectomy or 
had a short period of medical therapy, not 
exceeding one month, before trabeculectomy. 
Patients were excluded if they had less than 
3 years of continuous follow up, concomitant 
ocular diseases likely to affect glaucoma 
treatment-related resource consumption, or 
were subsequently enrolled at any time in a 
clinical trial. Patients who were not compliant 
with therapy were also excluded. 
Collected  data  included  patient 
demographics, number of ophthalmology 
clinic visits, number and type of glaucoma 
medications and surgeries, perioperative drugs 
in subjects who had undergone glaucoma 
surgery, and any postoperative procedure. All 
clinical tests documented in the files were also 
recorded. Glaucomatous optic disc appearance 
was categorized using the modified grading 
by Jay13 as follows:
a.  Stage 1: Suspicious shape of the optic 
nerve, but cup/disc ratio less than or 
equal to 0.6.
b.  Stage 2: Pathological: cup/disc ratio 
greater than 0.6, but less than 0.9.
c.  Stage 3: End stage: cup/disc ratio greater 
than or equal to 0.9.
The hospital pharmacy, the accounting 
department, and four nearby pharmacies were 
consulted to provide available unit costs for 
surgical procedures and medications extracted 
from the case records. The direct annual cost 
of treatment per person-year, including a 
breakdown of costs attributed to glaucoma 
surgeries, cataract extractions, and glaucoma 
medications, was calculated for all patients. 
The costs were measured in Nigerian Naira 
(N) and expressed in United States Dollars 
($). The exchange rate during the period of the 
study was N 130.00 to $1.00. The costs of drugs 
or surgery used for the study were based on 
estimates in November 2008.
A 5 ml bottle of an ocular medication 
prescribed twice daily or its equivalent (for 
example, a 2.5 ml bottle of a medication 
prescribed once daily) was assumed to represent 
a one-month supply for any given patient. Data 
on medication usage were collected at every 
visit and patients were assumed to adhere 
fully to medical regimens unless otherwise 
noted in the case records. The cost of therapy 
was calculated from the perspective of patients 
and only direct costs of drugs and surgery 
were considered. Only out-of-pocket payments 
were considered as none of the subjects had 
insurance policies.Cost of Glaucoma Treatment; Omoti et al
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Socio-economic status was classified using 
the patient’s occupation as modified from the 
British Registrar General’s Classification.14 
Class I comprises higher professions, such as 
medical doctors, engineers, businessmen, etc. 
Class II includes lesser professions such as 
nurses, teachers, etc. Class III consists of skilled 
workers such as typists, clerks, technicians, 
etc. Class IV comprises semi-skilled workers 
such as petty traders, machine operators, etc. 
Class V includes unskilled workers such as 
subsistence farmers, housewives, etc.
Data Analysis
In order to calculate the number of resources 
consumed per person-time, the total number of 
each consumed resource was added and then 
divided by the total number of follow-up visits. 
For patients who underwent surgery, the cost 
of surgery, hospital stay, and preoperative, 
intraoperative and postoperative drugs were 
calculated as the total cost of surgery. If the 
patient needed additional drugs to control 
intraocular pressure (IOP) or additional surgery 
for complications, these were also added to the 
cost of trabeculectomy in the surgery group. 
Data obtained from this study were analyzed 
using the Instat GraphPad version 2.05a software 
(GraphPad Software Inc., La Jolla, CA, USA). 
Mean and standard deviations (SD) of the costs 
of drugs and surgery were compared using the 
student t-test. 95% confidence intervals (95%CI) 
and the standard error of mean (SEM) were 
also determined. P-values less than 0.05 were 
considered significant. Factors affecting the cost 
of glaucoma therapy were determined using 
the student t-test and the one way analysis of 
variance (ANOVA) where appropriate.
RESuLTS
Overall, 308 new patients who attended the 
eye clinic during the period of the study were 
diagnosed with POAG or normal tension 
glaucoma. Of these, 108 subjects (35.06%) met 
the inclusion criteria which included 78 male 
(72.22%) and 30 female (27.78%) patients with 
mean age of 58.14±10.8 (range 22 to 76) years. 
The age and sex distribution of study subjects 
is shown in figure 1. Sixteen patients (14.81%) 
were illiterate, 6 (5.56%) had primary education, 
26 (24.07%) had secondary education, and 60 
(55.56%) had tertiary education. Socio-economic 
status of the patients is shown in table 1. Ninety 
patients (83.33%) received medical therapy and 
18 patients (16.67%) underwent surgery.
The cost of commonly available drugs in 
Benin City, Nigeria is shown in table 2. Most 
subjects used topical preparations but some were 
on acetazolamide tablets. The presented price 
of acetazolamide was the cost of one month 
of therapy with one tablet three times daily. 
The mean annual cost of medical therapy 
was US$ 273.47±174.42, SEM = $ 31.85, median = 
$ 261.35, and 95% CI = $ 208.35-338.60 (range, 
$ 41.54 to $ 729.23). The mean monthly cost of 
medical therapy was $ 22.78±14.53, SEM = $ 2.65, 
median = $ 21.78, and 95% CI= $ 17.21-28.21 
(range, $ 3.46 to $ 60.77). The mean daily cost 
of medical treatment was $ 0.75±0.48, SEM = 
$ 0.09, median = $ 0.72, and 95% CI = $ 0.57-
0.93 (range, $ 0.11 to $ 2.00). 
Social class Number of patients
I.   Higher professions 38 (35.19%)
II.   Lesser professions 39 (36.11%)
III.  Skilled workers 19 (17.59%)
IV.  Semi-skilled 4 (3.70%)
V.  Unskilled 8 (7.41%)
Total 108 (100%)
Table 1. Socioeconomic status of glaucoma patients
Figure 1. Age and sex distribution of glaucoma patients.Cost of Glaucoma Treatment; Omoti et al
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The lowest annual cost of medical therapy 
was associated with monotherapy with 
timolol maleate 0.5% drops, while the highest 
annual cost of medical therapy was related to 
combination therapy with latanoprost 0.005% 
(Xalatan) or travoprost (Travatan), dorzolamide 
(Trusopt) or brinzolamide (Azopt), and timolol 
maleate 0.5% (Timoptol).
The cost of trabeculectomy in the University 
of Benin Teaching Hospital was $ 103.85. The 
cost of perioperative drugs was $ 46.31, and 
that for an average 4-day hospital stay was 
$ 33.85. Thus, the total cost of trabeculectomy 
per eye was $ 184.00.
The mean annual cost of surgical treatment 
was US$ 283.78±202.95, median = $ 253.92, 
and 95% CI = $ 70.76-496.79 (range, $ 61.33 to 
$ 592.63). The mean monthly cost of surgical 
treatment was $ 23.65±16.91, median = $ 21.16, 
and 95% CI = $ 5.90-41.40 (range, $ 6.11 to 
$ 49.38). The mean daily cost of surgical 
treatment was $ 0.79±0.56, median = $ 0.71, 
and 95% CI = $ 0.20-1.38 (range, $0.17 to 1.65). 
Patients with the lowest annual cost of 
surgical therapy were those who had successful 
trabeculectomy without additional need for 
medical therapy for IOP control. Only 3 of 18 
patients (16.67%) had complete success with 
trabeculectomy and did not require additional 
medical treatment. Patients with the highest 
annual cost of surgical therapy were those 
who had unsuccessful trabeculectomy with 
additional need for medical therapy for IOP 
control and cataract surgery.
There was no significant difference between 
the mean cost of medical and surgical therapy 
(t=1.134, df=2, P=0.37). 
The cost of medical therapy according 
to the number of prescribed medications is 
demonstrated in table 3, which shows that 
cost rises as the number of medications 
increases. The cost of surgical therapy is 
shown in table 4, which shows that the cost 
of surgical therapy was highest in patients 
who developed complications and those who 
required reoperations or additional cataract 
No. of glaucoma medications No. of patients
Mean annual cost
(uS$)
Mean monthly cost (uS$)
Mean daily cost
(uS$)
1 15 (16.67%) $ 158.22 $ 13.18 $ 0.44
2 54 (60.00%) $ 312.55 $ 26.05 $ 0.88
3 17 (18.89%) $ 393.42 $ 32.78 $ 1.09
4 4 (4.44%) $ 553.85 $ 46.15 $ 1.54
Table 3. Cost of glaucoma medications over 3 years
Drug (volume) Trade name Manufacturer unit cost (N) unit cost (uS$)
Timolol (5ml) Timolol 0.5% Hovid 400.00 3.08
Timolol (5ml) Timolol 0.5% Martindale 400.00 3.08
Timolol (5ml) Nyolol 0.5% Novartis 900.00 6.92
Timolol (5ml) Optimol 0.5% Ashford 450.00 3.46
Timolol (5ml) Cusimolol 0.5% Alcon 650.00 4.62
Timolol (5ml) Timoptol 0.5% Merck, Sharpe & Dohme-Chibret 1,100.00 8.46
Betaxolol (5ml) Betoptic 0.5% Alcon 900.00 6.92
Pilocarpine (10ml) Pilocarpine 2%, 4% Martindale 450.00 3.46
Pilocarpine (10ml) Pilocarpine 2%, 4% Drugfield 450.00 3.46
Pilocarpine (10ml) Pilocarpine 2%, 4% Cusi 500.00 3.85
Dorzolamide (5ml) Trusopt 2% Merck, Sharpe & Dohme 3,450.00 26.54
Brinzolamide (5ml) Azopt Alcon 2,800.00 21.54
Latanoprost (2.5ml) Xalatan 0.005% Pfizer 4,200.00 32.31
Latanoprost (2.5ml) Xalost 0.005% Taejoon Pharm 3,300.00 25.38
Latanoprost (2.5ml) Prostan 0.005% ShanDong LuNan Better 2,700.00 20.77
Travoprost (2.5ml) Travatan 40μg/ml Alcon 4,500.00 34.62
Acetazolamide Acetomid (250mg tablets) Hovid 900.00 6.92
Table 2. Commonly available antiglaucoma drugs and their unit costCost of Glaucoma Treatment; Omoti et al
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surgery. Older age and advanced stages of 
glaucoma were significantly associated with 
higher costs of therapy (Table 5). 
DISCuSSION
Large-scale, prospective, randomized multicenter 
trials have provided evidence that lowering 
IOP in glaucoma can arrest the progression 
to blindness.15,16 Glaucoma is most commonly 
treated with topical medications in developed 
countries; surgery is usually performed if 
medications fails to lower IOP adequately.6 
Glaucoma drugs are commonly divided into 
six main groups: prostaglandin analogues, 
β-blockers, miotics, sympathomimetics, carbonic 
anhydrase inhibitors, and combination drugs. 
For more than 20 years, topical β-blockers 
dominated the market, overtaking the older 
miotics and sympathomimetics in volume of 
sales.9 However, in the past decade a number 
of new drugs have been introduced, which have 
had a profound effect on the management of 
glaucoma.6,9
The majority of patients in the present 
study were managed medically which is 
contrary to what is expected based on reports 
that trabeculectomy is the standard form of 
treatment for patients with primary open 
angle glaucoma in developing countries.7 This 
may reflect a change in the choice of therapy, 
probably because of the range of effective drugs 
now available, and the poor acceptability of 
glaucoma surgery in Benin City, Nigeria.8 A 
low proportion of surgical management has 
also been reported from Western Nigeria, where 
only 8.2% of a series of glaucoma patients had 
trabeculectomy.17 Although the majority of our 
patients had tertiary education and belonged 
to social classes I and II, the annual income in 
Nigeria is much less than that of developed 
countries. Subjects with tertiary education 
Type of surgery No. of patients
Mean annual cost
(uS$)
Mean monthly cost
(uS$)
Mean daily cost
(uS$)
Trabeculectomy only 3 (16.67%) $ 61.33 $ 5.11 $ 0.17
Trabeculectomy plus drugs for less than 1 year 3 (16.67%) $ 296.72 $ 24.73 $ 0.82
Trabeculectomy plus drugs for more than 1 year 2 (11.11%) $ 218.26 $ 18.19 $ 0.61
Trabeculectomy plus drugs for more than 2 years 1 (5.56%) $ 139.79 $ 11.65 $ 0.39
Trabeculectomy with postoperative complications 
and/or repeat surgery
6 (33.33%) $ 408.72 $ 34.06 $ 1.14
Table 4. Cost of surgical therapy over 3 years
Factors Frequency Mean annual cost ± SD (uS$) Test df P-value
Age
< 40 years 18 (16.67%) $ 249.00 ± 49.54
F=4.034 107 0.0205 40-60 years 48 (44.44%) $ 278.31 ± 58.12
> 60 years 42 (38.89%) $ 294.31 ± 58.05
Sex
Male 78 (72.22%) $ 280.62 ± 58.98
t=0.6351 106 0.5267
Female 30 (27.78%) $ 272.69 ± 55.56
Socioeconomic status
Higher professions 38 (35.19%) $ 279.75 ± 58.88
F=0.05572 107 0.9941
Lesser professions 39 (36.11%) $ 282.56 ± 58.18
Skilled workers 19 (17.59%) $ 286.40 ± 52.95
Semi-skilled 4 (3.70%) $ 275.92 ± 50.58
Unskilled 8 (7.41%) $ 282.87 ± 53.72
Stage of glaucoma
Stage 1 42 (38.89%) $ 257.38 ± 56.40
F=8.188 107 0.0005 Stage 2 35 (32.41%) $ 272.65 ± 54.10
Stage 3 31 (28.70%) $ 309.69 ± 54.86
Table 5. Factors affecting cost of therapy
df, degree of freedomCost of Glaucoma Treatment; Omoti et al
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were those who had post-secondary education 
such as university, polytechnic, or other 
professional education. The minimum wage 
in Nigeria is only N 5,500.00 ($42.31) monthly 
and N 66,000.00 ($507.69) per annum.18 This 
amount is just slightly higher than the price 
of latanoprost or travoprost. These figures 
imply that a patient on minimum wage cannot 
afford a combination therapy which includes 
prostaglandin analogues, even if he/she spends 
all his/her income. The average patient will 
also have to save all of his/her monthly income 
for 5 months to afford trabeculectomy in one 
eye. Even patients in higher professions still 
have to spend a significant amount of their 
earnings to be able to pay for combination 
therapy or surgery.
The most expensive drugs were the 
prostaglandin analogues, travoprost (Travatan) 
and latanoprost (Xalatan). Other expensive 
drugs included topical carbonic anhydrase 
inhibitors, dorzolamide and brinzolamide. 
Although other drugs, such as brimonidine 
(Alphagan), are available in Benin City, none 
of the patients in this series used them. These 
drugs were usually not prescribed because 
they were not commonly available. The least 
expensive topical drugs were β-blockers and 
miotics. The oral carbonic anhydrase inhibitor, 
acetazolamide, was also inexpensive. Although 
acetazolamide is not indicated for long term 
use, it was commonly prescribed because of 
its efficacy in the short term and because poor 
patients could afford a few tablets at a time, 
thus reducing non-compliance due to the cost 
of drugs.
There was no significant difference in 
the mean annual, monthly, or daily costs of 
medical versus surgical treatment. The average 
cost of surgical therapy was however, slightly 
higher over a 3-year period. This is in contrast 
to what is expected, since surgical patients 
are expected to pay once for their procedure 
while patients on medical therapy continue 
to purchase drugs indefinitely. Eventually, 
medical therapy should become more expensive. 
Unfortunately, many glaucoma patients who had 
undergone trabeculectomy needed additional 
medical therapy for IOP control and may also 
have incurred extra costs for management of 
postoperative complications such as cataracts, 
infection, bleb-related complications, etc. 
Trabeculectomy tends to fail over time because 
of fibroblastic proliferation and subconjunctival 
fibrosis which occurs during the process of 
wound healing.19 Adjunctive use of antifibrotic 
agents such as mitomycin C at the site of 
surgery has significantly reduced the risk of 
bleb failure.20 Sherwood et al21 have argued 
that it is wrong to believe that a one-step 
surgery will save money. Their 1991 estimates 
show that the cost of bilateral uncomplicated 
glaucoma surgery roughly equals 8 years of 
medical treatment. Since about one third of the 
patients may need additional medical therapy 
or reoperations for failed surgery, premature 
cataract extraction, and other complications, the 
final cost of surgery may be even more. In the 
current study, patients who had complications 
and required additional procedures had the 
highest cost of surgical therapy.
The lowest cost of medical therapy was 
observed for monotherapy with timolol maleate 
0.5% which was slightly lower than that of 
successful and uncomplicated trabeculectomy 
not requiring additional medical therapy. 
However if these two groups of patients had 
been followed up for up to 5 years, the mean 
monthly cost of surgery ($3.06) would have been 
lower than the mean monthly cost of medical 
therapy ($3.46). If they were followed up for 
even longer, the difference would become 
more significant. Unfortunately, most of our 
glaucoma patients are usually lost to follow-up 
after a few years and many African patients 
will eventually have poorly controlled IOP 
after surgery because of the propensity for 
fibrosis. These patients will need additional 
medical therapy, revision of trabeculectomy, 
or repeat surgery, thus increasing the cost of 
surgical therapy. 
Older age and late stages of glaucoma 
were significantly associated with higher costs 
of glaucoma therapy. This is because patients 
who present with advanced disease are treated 
more vigorously with more medications and 
surgery. In these patients the target IOP is 
set lower because optic nerve damage is Cost of Glaucoma Treatment; Omoti et al
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severe. Similar findings have been reported 
from Europe10 and the United States11. Older 
patients are more likely to present later and 
with advanced disease.
Although our study groups were non-
homogenous, this study was designed to look 
back and measure what it cost for the average 
patient to undergo medical therapy or surgery, 
and compare them. The annual cost of surgery 
was used rather than the onset surgery cost 
and maintenance cost, in order to correct the 
assumption that surgery is a one-off event, 
when in reality, many cases require additional 
medical therapy. Therefore, the average cost 
of surgery should also include the cost for 
management of complications, as well as any 
additional therapy that may be required to 
control IOP.
One  limitation  of  this  study  is  its 
retrospective nature. Furthermore, patients 
were not randomized to medical versus 
surgical therapy. Thus, the sample size was 
lopsided such that the majority of the patients 
were in the medical group and only a few 
underwent surgery. The therapeutic protocol 
was determined mainly by the level of IOP and 
the severity of the disease, as well as patients’ 
choice and ability of the patient to afford the 
prescribed treatment. Also, because the study 
is retrospective, details of indirect costs could 
not be elicited. The study thus focused on direct 
costs of surgery and drugs. The confounding 
role of age, disease severity, and socio-economic 
status was not taken into consideration. In 
the original study population from which the 
study sample was selected, the majority of 
patients were lost to follow up before 3 years. 
Poor follow up in glaucoma patients had been 
reported in other studies from Nigeria.7
In conclusion, the mean cost of medical 
therapy was comparable to that of surgical 
therapy over a 3-year period. The prostaglandin 
analogues were the most expensive drugs, 
while β-blockers and miotics were the most 
affordable. Older age and advanced glaucoma 
were associated with higher costs of glaucoma 
therapy. The minimum wage in Nigeria can 
barely cover the cost of newer antiglaucoma 
drugs or surgery.
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